Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
inadvertently gave Priorix intramuscularly instead of Subcutaneous; This non-serious case was reported by a consumer via sales rep and described the occurrence of subcutaneous injection formulation administered by other route in a female patient who received MMR (Priorix) for prophylaxis. On 23-APR-2025, the patient received Priorix. On 23-APR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: inadvertently gave Priorix intramuscularly instead of Subcutaneous). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-APR-2025 Nurse inadvertently gave Priorix intramuscularly instead of subcutaneous, which led to subcutaneous injection formulation administered by other route.